Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells

Carcinogenesis

Volumn 32, Issue 12, 2011, Pages 1758-1772

  Nakamura, Satoki ^a   Takemura, Tomonari ^a   Tan, Lin ^a   Nagata, Yasuyuki ^a   Yokota, Daisuke ^a   Hirano, Isao ^a   Shigeno, Kazuyuki ^a   Shibata, Kiyoshi ^a   Fujie, Michio ^a   Fujisawa, Shinya ^b   Ohnishi, Kazunori ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABL KINASE INHIBITOR; BCR ABL PROTEIN; CASPASE 3; CASPASE 9; MESSENGER RNA; PHOSPHOTRANSFERASE INHIBITOR; RAB45 PROTEIN; RNA; SYNAPTOPHYSIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPHOID PROGENITOR CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; ENZYME ACTIVATION; GENES, ABL; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIALS; NEOPLASTIC STEM CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RAS GUANINE NUCLEOTIDE EXCHANGE FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER;

EID: 81855217392     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr205     Document Type: Article

References (54)

1. Kurzrock,R. et al. (1988) The molecular genetics of Philadelphia chromosome- positive leukemias. N.Engl.J.Med., 319, 990-998.
2. Rudkin,C.T. et al. (1964) DNA contents of chromosome ph1 and chromosome 21 in human chronic granulocytic leukemia. Science, 144, 1229-1231.
3. Shtivelman,E. et al. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 315, 550-554.
4. Lugo,T.G. et al. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247, 1079-1082.
5. Daley,G.Q. et al. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247, 824-830.
6. Belloc,F. et al. (1997) Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ., 4, 806-814.
7. Cortez,D. et al. (1995) Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol., 15, 5531-5541.
8. Deininger,M.W. et al. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90, 3691-3698.
9. Mahon,F.X. et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96, 1070-1079.
10. Amarante-Mendes,G.P. et al. (1998) Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood, 91, 1700-1705.
11. Kurosu,T. et al. (2009) Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res., 69, 3927-3936.
12. Horita,M. et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of BclxL. J. Exp. Med., 191, 977-984.
13. Jaiswal,S. et al. (2003) Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc. Natl Acad. Sci. USA, 100, 10002-10007.
14. Cirinna,M. et al. (2000) Bcl-2 expression restores the leukemogenic potential of a Bcr/Abl mutant defective in transformation. Blood, 96, 3915-3921.
15. Dai,Y. et al. (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem., 279, 34227-34239.
16. Aichberger,K.J. et al. (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 105, 3303-3311.
17. Salomoni,P. et al. (2000) Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood, 96, 676-684.
18. Essafi,A. et al. (2005) Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in BcrAbl-expressing cells. Oncogene, 24, 2317-2329.
19. Luciano,F. et al. (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene, 22, 6785-6793.
20. Kuribara,R. et al. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol. Cell. Biol., 24, 6172-6183.
21. Aichberger,K.J. et al. (2005) Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res., 65, 9436-9444.
22. Amarante-Mendes,G.P. et al. (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up-regulation of Bcl-xL. Oncogene, 16, 1383-1390.
23. Shin,S. et al. (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 40, 1117-1123.
24. Ambrosini,G. et al. (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3, 917-921.
25. McKay,T.R. et al. (2003) Procaspase 3 expression in ovarian carcinoma cells increases surviving transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene, 22, 3539-3547.
26. Chen,J. et al. (2000) Down-regulation of survivin by antisense oligonucleo-tides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia, 2, 235-241.
27. Pereira-Leal,J. et al. (2001) Evolution of the Rab family of small GTP-binding proteins. J. Mol. Biol., 313, 889-901.
28. Hutagalung,H.A. et al. (2011) Role of Rab GTPases in membrane traffic and cell physiology. Physiol. Rev., 91, 119-149.
29. Chia,W. et al. (2009) Emerging roles for Rab family GTPases in human cancer. Biochem. Biophys. Acta, 1795, 110-116.
30. Mosesson,Y. et al. (2008) Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer, 8, 835-850.
31. Wang,X. et al. (2000) Regulation of vesicle trafficking in Madin-Darby canine kidney cells by Rab11a and Rab25. J. Biol. Chem., 275, 29138-29146.
32. Cheng,K. et al. (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat. Med., 10, 1251-1256.
33. Goldenring,J.R. et al. (2011) Rab25 as a tumor suppressor in colon carcinogenesis. Br. J. Cancer, 104, 33-36.
34. Maat,W. et al. (2008) Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. Invest. Ophthalmol. Vis. Sci., 49, 1291-1298.
35. Nakamura,S. et al. (2010) The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis, 31, 2012-2021.
36. Nakamura,S. et al. (2008) KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. Leuk. Res., 32, 1358-1365.
37. Junttila,M.R. et al. (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J., 22, 954-965.
38. Park,S.J. et al. (2005) The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol., 146, 506-513.
39. Raitano,A.B. et al. (1997) Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta, 1333, 201-216.
40. Bedi,A. et al. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2-M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86, 1148-1158.
41. Pfeffer,S. (2005) A model for Rab GTPase localization. Biochem. Soc. Trans., 33, 627-630.
42. Sweetser,D.A. et al. (2005) Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. Genes Chromosomes Cancer, 44, 279-291.
43. Shintani,M. et al. (2007) Characterization of Rab45/RASEF containing EF- hand domain and a coiled-coil motif as a self-associating GTPase. Biochem. Biophys. Res. Commun., 357, 661-667.
44. Hengartner,M.O. (2000) The biochemistry of apoptosis. Nature, 407, 770-776.
45. Kurosu,T. et al. (2009) Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res., 69, 3927-3936.
46. Badran,A. et al. (2003) Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res., 23, 589-592.
47. Moriai,R. et al. (2001) Quantitative analysis of the anti-apoptotic gene surviving expression in malignant haematopoietic cells. Anticancer Res., 21, 595-600.
48. Wang,Z. et al. (2005) Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res., 65, 8224-8232.
49. Parmar,S. et al. (2004) Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J. Biol. Chem., 279, 25345-25352.
50. Dumka,D. et al. (2009) Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk. Lymphoma, 50, 2017-2029.
51. Han,J. et al. (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 265, 808-811.
52. Wong,S. et al. (2003) Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood, 101, 4088-4097.
53. Druker,B.J. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344, 1031-1037.
54. Scherr,M. et al. (2003) Specific inhibition of BCR-ABL gene expression by small interfering RNA. Blood, 101, 1566-1569.